Ilan Goldenberg

Risk of Mortality for Ventricular Arrhythmia in Ambulatory LVAD Patients

Risk of Mortality for Ventricular Arrhythmia. Background: There are limited data regarding the incidence and prognostic significance of ventricular arrhythmias (VA) in ambulatory continuous flow left ventricular assist device (LVAD) patients.

Cost-effectiveness of Implanted Defibrillators in Young People with Inherited Cardiac Arrhythmias

Background: The implanted cardioverter‐defibrillator (ICD) has been shown to improve survival in adult patients with high risk acquired cardiac disease, with a cost‐effectiveness ratio in the range of

Effect of elapsed time from coronary revascularization to implantation of a cardioverter defibrillator on long-term survival in the MADIT-II trial.

30,000 to

Implantable cardioverter defibrillator efficacy and chronic kidney disease: competing risks of arrhythmic and nonarrhythmic mortality.

185,000 per quality‐adjusted‐life‐year saved. However, data on the benefit and cost‐effectiveness of device therapy in high‐risk patients with inherited cardiac disorders are limited.

Polymorphism in the Cholesteryl Ester Transfer Protein Gene and the Risk of Early Onset Myocardial Infarction among Cigarette Smokers

Coronary Revascularization and Long‐Term Mortality in MADIT‐II.u2002Introduction: Coronary revascularization (CR) may reduce arrhythmia risk and improve long‐term outcome in patients with left ventricular dysfunction. This study was designed to evaluate the effect of elapsed time from CR on long‐term mortality and arrhythmic risk among patients who receive an implantable cardioverter defibrillator (ICD).

Effectiveness of Cardiac Resynchronization Therapy in Diabetic Patients with Ischemic and Nonischemic Cardiomyopathy

Implantable Cardioverter Defibrillator Efficacy and Chronic Kidney Disease: Competing Risks of Arrhythmic and Nonarrhythmic Mortality ILAN GOLDENBERG, M.D.∗,† and ARTHUR J. MOSS, M.D.∗ From the ∗Division of Cardiology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA; and †Heart Institute and Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, Israel

Genotype-Specific Risk Stratification and Management of Patients with Long QT Syndrome

Background: Cigarette smoking and the common B1 allele of the TaqIB polymorphism have both been reported to be associated with increased cholesteryl ester transfer protein (CETP) activity and altered lipoprotein levels. Thus, it is possible that the combined presence of these two respective environmental and genetic factors may enhance cardiovascular risk. We hypothesized that susceptibility to early onset myocardial infarction (MI) among cigarette smokers may be related to the presence of TaqIB polymorphism in the CETP gene.

Effectiveness of Cardiac Resynchronization Therapy with Defibrillator in At‐Risk Black and White Cardiac Patients

Background: Diabetes mellitus (DM) increases the risk for the development of both ischemic and nonischemic cardiomyopathy. We aimed to identify differences in response to cardiac resynchronization therapy with a defibrillator (CRT‐D) among DM patients with ischemic or nonischemic cardiomyopathy.

Ion Channel Mechanisms Related to Sudden Cardiac Death in Phenotype‐Negative Long‐QT Syndrome Genotype–Phenotype Correlations of the KCNQ1(S349W) Mutation

Long QT syndrome (LQTS) is an inherited disorder associated with life‐threatening ventricular arrhythmias. An understanding of the relationship between the genotype and phenotype characteristics of LQTS can lead to improved risk stratification and management of this hereditary arrhythmogenic disorder. Risk stratification in LQTS relies on combined assessment of clinical, electrocardiographic, and mutations‐specific factors. Studies have shown that there are genotype‐specific risk factors for arrhythmic events including age, gender, resting heart rate, QT corrected for heart rate, prior syncope, the postpartum period, menopause, mutation location, type of mutation, the biophysical function of the mutation, and response to beta‐blockers. Importantly, genotype‐specific therapeutic options have been suggested. Lifestyle changes are recommended according to the prevalent trigger for cardiac events. Beta‐blockers confer greater benefit among patients with LQT1 with the greatest benefit among those with cytoplasmic loops mutations; specific beta‐blocker agents may provide greater protection than other agents in specific LQTS genotypes. Potassium supplementation and sex hormone–based therapy may protect patients with LQT2. Sodium channel blockers such as mexiletine, flecainide, and ranolazine could be treatment options in LQT3.

Prolonged QT in a 13‐Year‐Old Patient with Down Syndrome and Complete Atrioventricular Canal Defect

There are limited data regarding racial differences in response to cardiac resynchronization therapy with defibrillator (CRT‐D).